对《阿那白滞素治疗掌跖脓疱病：一项随机、双盲、多中心、两阶段、适应性安慰剂对照试验（APRICOT）的结果》的回应：作者的回复

Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.

作者信息

Cro S, Smith C H

机构信息

Imperial Clinical Trials Unit, Imperial College London, London, W12 7RH, UK.

St John's Institute of Dermatology, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, UK.

出版信息

Br J Dermatol. 2022 May;186(5):909-910. doi: 10.1111/bjd.20944. Epub 2022 Mar 2.

DOI:10.1111/bjd.20944

PMID:34878650

Abstract

We believe that there is significant interest in the role of IL-1 in the pathomechanism of palmoplantar pustulosis. However, the APRICOT study failed to demonstrate a therapeutic effect of the IL-1 receptor antagonist. So, we recommend that the authors perform an additional subgroup analysis based on the presence or absence of plaque psoriasis.

摘要

我们认为，白细胞介素-1（IL-1）在掌跖脓疱病发病机制中的作用备受关注。然而，APRICOT研究未能证明IL-1受体拮抗剂的治疗效果。因此，我们建议作者根据是否存在斑块状银屑病进行额外的亚组分析。